Investigating how the CD47 pathway affects rheumatoid arthritis and its treatment
Role of the CD47 Pathway in Rheumatoid Arthritis Pathogenesis and Treatment
['FUNDING_R01'] · UNIVERSITY OF ROCHESTER · NIH-10890114
This study is looking at how a specific pathway in the immune system, called the CD47 pathway, affects rheumatoid arthritis and is testing whether combining new treatments with current therapies can help improve the health of people with this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10890114 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the CD47 pathway in the development and treatment of rheumatoid arthritis (RA). It aims to explore how CD47 influences immune cell behavior and tissue pathology in RA patients by analyzing patient samples and using mouse models. The study will evaluate the effectiveness of combining anti-CD47 therapies with existing biologic treatments to improve patient outcomes. By examining these interactions, the research seeks to identify new therapeutic strategies for managing RA.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who may not be responding adequately to current therapies.
Not a fit: Patients with rheumatoid arthritis who are already effectively managed with existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for rheumatoid arthritis that target both inflammation and bone damage.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for treating autoimmune diseases, suggesting potential for success in this approach.
Where this research is happening
ROCHESTER, UNITED STATES
- UNIVERSITY OF ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KORMAN, BENJAMIN DOUGLAS — UNIVERSITY OF ROCHESTER
- Study coordinator: KORMAN, BENJAMIN DOUGLAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.